Bio-Rad Laboratories (BIO)
Health Care · life sciences tools & services · NYSE
Bio-Rad provides essential tools and services for life science research and clinical diagnostics to help advance scientific discovery and improve patient outcomes.
What Bio-Rad Laboratories does
Bio-Rad Laboratories develops, manufactures, and markets a broad range of products for the life science research and clinical diagnostics markets. Its portfolio includes instruments, software, consumables, reagents, and content for the study of biological processes and the analysis of clinical samples. The company also maintains a strategic investment position in Sartorius AG.
Themes: life science research, clinical diagnostics, laboratory instrumentation
Fundamentals
- Price$380.03 as of 2026-08-21 close
- Market cap$10.5B as of 2026-08-21
- 1-year return+33.3% 2025-08-21 close $285.03 → 2026-08-21 close $380.03
- P/E43.49 as of 2026-08-24
- Net margin+8.6% as of 2026-08-24
- Gross margin+51.9% as of 2026-08-24
- ROE+3.1% as of 2026-08-24
- Debt / equity0.17 as of 2026-08-24
- Revenue growth (YoY)+1.4% as of 2026-08-24
- Revenue CAGR (3y)-2.7% SEC XBRL
- Beta1.08 as of 2026-08-24
- Last reported earnings2026-08-04 SEC EDGAR Form 8-K (Item 2.02)
How BIO compares in its sector
- price-to-earnings ratiomiddle range 203 covered Health Care peers, as of 2026-08-24
- net profit margintop 25% 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRbottom 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)top 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
BIO is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no shareholder return data.
Short-term score
47.3 #965 of 1,704 scored · #170 of 240 in Health Care
Volume and participation 87th: trading volume is about normal versus its 30-day average; trend 82nd: a strong uptrend, with buyers in control; weakest is setup 28th: over the past year its closes ranged, and it has retraced essentially none of its move over the past year — 0% of it. Its score is docked 10 points for overextended (RSI above 75 or stochastic above 90).
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How Bio-Rad Laboratories looks technically
Bio-Rad Laboratories (BIO) is trading 27.3% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 17 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 42, with buyers in control. Momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 78, in overbought territory (above 70). It just made a new 20-day high, pushing above its recent trading range. It is 1.5% below its 52-week high (its highest price of the past year).
Trend
9
| Distance from the 200-day | it is trading 27.3% above its 200-day average, the long-term trend line — a longer-term uptrend | +27.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $315.97 | $315.97 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $298.53 | $298.53 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 44 calendar days ago — the swings before that are what the structure reading is measured on | 44 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 281.79. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 17 trading days ago — a "golden cross", a bullish long-term signal | 17 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 27.3% above | +27.3% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 42, with buyers in control | 41.9 |
Momentum
3
| 14-day RSI | momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 78, in overbought territory (above 70) | 77.8 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($325.31 to $385.92) — its "stochastic" reading is 90 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 90.3 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 30 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $385.92 | $385.92 |
|---|---|---|
| From the 52-week high | it is 1.5% below its 52-week high (its highest price of the past year) | -1.5% |
| Above the 52-week low | it is 60.5% above its 52-week low (its lowest price of the past year) | +60.5% |
| Below the 52-week high | it is 1.5% below its highest point of the past year | 1.5% |
| Since a 20-day breakout | it just made a new 20-day high, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day high, pushing above its recent trading range | 1 session |
| All-time high | its highest closing price on record is $832.70 (set on 2021-09-02) | $832.70 |
| Given back of the 52-week move | over the past year its closes ranged ($241.71 to $380.03), and it has given back essentially none of its rise from last year’s low — 0% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $290.12 to $294.55. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.0% |
| From the all-time high | it is 54.4% below its all-time high | -54.4% |
| Nearest price level | it is trading 8.5% above a support level at $347.58 — a price it turned at five times since 2024-09-19, most recently on 2025-10-27. Since 2024-08-21 it has 14 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -8.5% |
| All-time low | its lowest closing price on record is $50.25 (set on 2005-09-22) | $50.25 |
| Above the all-time low | it is 656.3% above its all-time low | +656.3% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 63rd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $10.91 between its high and its low — about 2.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $10.91 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $313.58 and $382.04 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $313.58 – $347.81 – $382.04 |
| Typical daily range (% of price) | its price moves about 2.9% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 2.9% |
| Stretch from the 200-day average | it is trading 7.5 daily ranges above its 200-day average price (27.3% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 7.5 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.29× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Price gaps
1
| Gap filled | a 2.1% gap up opened on 2026-08-05 has been "filled" 12 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 12 sessions ago |
|---|
Price streaks
1
| Closing streak | it has closed higher 3 sessions in a row, a +7.75% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 3 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 23.6 percentage points (the stock gained 26.0% while the market gained 2.3%) | +23.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 29.4 percentage points (the stock gained 32.5% while the market gained 3.1%) | +29.4% |
| vs market, 6 months | over the past 6 months this stock beat the market by 29.0 percentage points (the stock gained 40.1% while the market gained 11.1%) | +29.0% |
| vs market, 12 months | over the past 12 months this stock beat the market by 12.8 percentage points (the stock gained 33.3% while the market gained 20.5%) | +12.8% |
Signal agreement
2
| Bullish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: its RSI momentum gauge is overbought (a stretched reading), near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 30% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 3.5% of the share price. | +30.4% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 30% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $293.40 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +29.5% |
|---|---|---|
| Vs the average paid since it last reported | the price is 7% above the average price paid since it last reported on 2026-08-04 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $356.78 — a volume-weighted average of daily closes over 14 sessions, not a true tick-by-tick VWAP. | +6.5% |
Price levels it has turned at before
BIO last closed at $380.03 on 2026-08-21. Since 2024-08-21 it has turned at 14 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $347.58 | Support | 8.5% below the last close | turned there five times · 2024-09-19 to 2025-10-27 |
| $335.96 | Support | 11.6% below the last close | turned there three times · 2024-09-03 to 2025-11-25 |
| $328.72 | Support | 13.5% below the last close | turned there three times · 2024-10-16 to 2026-01-13 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $281.79.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Tested and reclaimed 200-day support · Overbought (14-day RSI above 70) · Near the 52-week high · Broke out to a new 20-day high | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingHold (3.00 mean, 1=Strong Buy…5=Strong Sell) — 5 analysts
- Mean price target$329.00 range $280.00 – $390.00; median $330.00
Analyst estimates, as of 2026-08-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for BIO
- Consensus EPS estimate$2.23 next reporting period, as of 2026-08-18
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["risks associated with investment in Sartorius AG","foreign currency exchange fluctuations","supply chain issues and reliance on international operations"]
What changed in the latest 10-Q
AI-assisted comparison of BIO's 10-Q filed 2026-04-30 against the prior one filed 2025-10-29.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-04-30) references consolidated financial statements for year ended December 31, 2025 and three months ended March 31, 2026
- Newer filing adds specific disclosure about Middle East regional conflicts escalation affecting EMEA region demand and logistics, particularly in Clinical Diagnostics segment
- Newer filing states expectation that Middle East conflict conditions will continue to adversely affect EMEA for remainder of 2026
- Newer filing includes Q1 2026 versus Q1 2025 results table with specific metrics (sales $592.1M vs $585.4M, gross profit 52.3% both periods, SG&A 35.9% vs 35.7%, R&D 10.6% vs 12.6%)
- Newer filing includes Q1 2026 currency neutral sales comparison showing 4.2% decrease
- Newer filing discloses Life Science segment sales of $228.5M essentially flat but currency neutral down 4.3%
- Newer filing discloses Clinical Diagnostics segment sales of $363.6M up 1.9% but currency neutral down 4.1%
- Newer filing references specific gross margin drivers: higher material costs, elevated fuel prices, reduced inventory scrap, and restructuring costs
- Newer filing states SG&A expense of $212.4M (35.9% of sales) versus $208.8M (35.7% of sales) with weaker U.S. dollar as primary driver
- Newer filing states R&D expense of $62.9M (10.6% of sales) versus $73.5M (12.6% of sales)
- Removed:
- Older filing (2025-10-29) references consolidated financial statements for year ended December 31, 2024 and three and nine months ended September 30, 2025
- Older filing contains no discussion of Middle East regional conflicts
- Older filing includes Q3 2025 versus Q3 2024 results table showing multiple periods and nine-month comparisons
- Older filing includes nine-month ended September 30 data in main results table
- Older filing references constrained academic research and biotech funding environment rather than identifying specific geopolitical conflicts
- Older filing cites lower reimbursement rates for diabetes testing in China as specific currency neutral sales driver
- Older filing discloses gross margin declines of 1.7 percentage points (Life Science) and 2.5 percentage points (Clinical Diagnostics)
- Older filing states higher employee-related and restructuring costs as primary SG&A driver
- Older filing references higher in-process R&D charges associated with an acquisition in prior year quarter
- Reworded:
- Older text 'Reduced government spending, along with ongoing challenges in the biopharma market' changed to newer 'need for governments to control their spending, along with ongoing challenges among small biotech companies' in 2026 filing
- Older text references 'biopharma market' whereas newer text references 'small biotech companies'
- Older filing states 'approximately 41%' U.S. sales; newer filing states 'approximately 39%' U.S. sales
- Older filing emphasizes 'Reduced government spending' while newer filing emphasizes 'need for governments to control their spending'
- Older filing discusses conditions expected 'through the rest of 2025' whereas newer filing discusses conditions expected 'through the rest of 2026'
- Notes:
- Both filings discuss different reporting periods (Q1 2026 vs Q3 2025), making year-over-year operational comparisons limited
- Newer filing text appears truncated at 'Interest expense for the first quarter of 2026 and 2025 w' preventing full assessment of non-operating results section
- Older filing also appears truncated at 'Foreign currency exchange (gains) losses, net consist prim' preventing full comparison of complete sections
Risk Factors
- Added:
- Newer filing includes Item 1A Risk Factors on page 35 (filed 2026-04-30)
- Newer filing presents three-month comparative financial statements for March 31, 2026 vs. December 31, 2025 (filed 2026-04-30)
- Newer filing shows March 31, 2026 balance sheet with total assets of $9,790.0 million (filed 2026-04-30)
- Newer filing reports three-month period net loss of $(527.1) million with $(738.2) million loss from change in fair market value of equity securities (filed 2026-04-30)
- Newer filing includes cash flow statement for three months ended March 31, 2026 showing net cash provided by operating activities of $108.1 million (filed 2026-04-30)
- Removed:
- Older filing included Item 1A Risk Factors on page 40 (filed 2025-10-29)
- Older filing presented nine-month comparative financial statements for September 30, 2025 vs. December 31, 2024 (filed 2025-10-29)
- Older filing showed September 30, 2025 balance sheet with total assets of $9,696.4 million (filed 2025-10-29)
- Older filing reported three-month and nine-month period results ending September 30, 2025 (filed 2025-10-29)
- Older filing included nine-month cash flow statement (filed 2025-10-29)
- Reworded:
- Balance sheet date changed from September 30, 2025 comparison to December 31, 2025 comparison (filed 2026-04-30)
- Income statement period changed from three-month and nine-month ended September 30 to three-month ended March 31 (filed 2026-04-30)
- Cash flow statement period changed from nine months ended September 30, 2025 to three months ended March 31, 2026 (filed 2026-04-30)
- Current maturities of long-term debt increased from $1.3 million to $400.5 million between December 31, 2025 and March 31, 2026 (filed 2026-04-30)
- Other investments decreased from $6,103.6 million to $5,311.8 million between December 31, 2025 and March 31, 2026 (filed 2026-04-30)
- Notes:
- The newer filing appears truncated in the cash flows section and does not show complete investing and financing activities
- Forward-looking statements section is identical in both filings; no substantive changes detected in that disclosure
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
- Last 180 days0 buys · 1 sell ($135597) — 1 selling insider
Most recent open-market transaction: 2026-05-11. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about BIO's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding BIO as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 2,395,781
- Reported value $667,823,840
reported quarterly holdings change (2025-12-31 → 2026-03-31): 1 new, 2 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
BIO had 1,412,268 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
Short interest as a percent of shares outstanding is not shown for BIO because the newest share count we hold predates that settlement by more than 180 days, and a buyback or issuance in between would move the base. The reported figures above are unaffected.
- Reported short interest (shares) 1,412,268
- Prior settlement (shares) 1,559,452
- Reported change -9.44%
- Days to cover (reported) 4.29
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Thermo Fisher Scientific (TMO)
- Danaher (DHR)
- Agilent Technologies (A)
- PerkinElmer (PKI)
- Waters Corporation (WAT)
- Roche Diagnostics
- Siemens Healthineers
- Becton Dickinson (BDX)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare BIO vs…
Bio-Rad Laboratories is found in…
Frequently asked questions
What does Bio-Rad Laboratories (BIO) do?
Bio-Rad Laboratories develops, manufactures, and markets a broad range of products for the life science research and clinical diagnostics markets. Its portfolio includes instruments, software, consumables, reagents, and content for the study of biological processes and the analysis of clinical samples. The company also maintains a strategic investment position in Sartorius AG.
What sector is Bio-Rad Laboratories (BIO) in?
Bio-Rad Laboratories (BIO) is classified in the Health Care sector. Its industry is life sciences tools & services. It trades on NYSE.
Who are Bio-Rad Laboratories's (BIO) competitors?
Notable peers of Bio-Rad Laboratories (BIO) include Thermo Fisher Scientific, Danaher, Agilent Technologies, PerkinElmer and Waters Corporation. This peer set is informational only — not financial advice.
Is Bio-Rad Laboratories (BIO) overbought or oversold right now?
Bio-Rad Laboratories (BIO) is currently in overbought territory (its 14-day RSI is 78, above 70) (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on BIO come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.